镭-223在转移性去势抵抗性前列腺癌治疗选择演变中的定位:欧洲专家工作组建议
欧洲专家工作组基于ERA 223试验结果——阿比特龙联合镭-223较阿比特龙联合安慰剂未改善症状性骨骼事件无生存期且骨折增加,尤其未用骨健康药物者——撰文讨论镭-223在转移性去势抵抗性前列腺癌治疗选择中的角色,并提供维持骨健康与延长生存治疗序贯的专家建议。
要点
- 镭-223是去势抵抗性前列腺癌骨转移患者的有价值治疗选择。
- 监测与维持骨健康对前列腺癌患者至关重要,应在启动雄激素剥夺治疗时考虑。
- ERA 223显示阿比特龙联合镭-223未改善症状性骨骼事件无生存期,且骨折增加。
核心结论
- 镭-223是去势抵抗性前列腺癌骨转移患者的有价值治疗选择。
- 监测与维持骨健康对前列腺癌患者至关重要,应在启动雄激素剥夺治疗时考虑。
研究设计与样本
- 欧洲专家工作组在会议讨论后撰文,基于包括ERA 223在内的证据提出观点与专家建议。
主要发现
- ERA 223显示阿比特龙联合镭-223较阿比特龙联合安慰剂未改善症状性骨骼事件无生存期。
- ERA 223中阿比特龙联合镭-223观察到骨折增加,尤其见于未接受骨健康药物(地舒单抗或唑来膦酸)的患者。
关键数值与推荐
- 工作组提供维持骨健康的专家建议。
- 工作组提供延长生存治疗序贯的专家建议。
- 工作组讨论镭-223在转移性去势抵抗性前列腺癌新兴治疗选择中的角色。
临床怎么用
- 监测与维持骨健康对前列腺癌患者至关重要,应在启动雄激素剥夺治疗时考虑。
- 镭-223是去势抵抗性前列腺癌骨转移患者的有价值治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several ongoing clinical trials are investigating novel therapies and combinations of existing therapies for the treatment of patients with metastatic castration-resistant prostate cancer. One such trial, ERA 223, has shown that the combination of abiraterone plus radium-223 did not improve symptomatic skeletal event-free survival compared with abiraterone plus placebo. Furthermore, an increase in bone fractures was observed with the combination of abiraterone and radium-223 in the study, particularly in patients not receiving bone health agents (denosumab or zoledronic acid). The results led to a change in the indication of radium-223 in Europe and also highlighted a need for greater awareness of bone health in patients with prostate cancer. Following a meeting to discuss these issues, we report in this article our views on the role of radium-223 within the emerging treatment options for patients with metastatic castration-resistant prostate cancer. We discuss best practices, and provide expert recommendations for preserving bone health and sequencing of life-prolonging therapies in patients with prostate cancer in order to achieve optimal outcomes. PATIENT SUMMARY: We provide recommendations on maintaining bone health, sequencing of treatments, and the role of radium-223 therapy in prostate cancer. Radium-223 is a valuable treatment option for patients with castration-resistant prostate cancer and bone metastases. Monitoring and maintaining bone health are essential for patients with prostate cancer, and should be considered at the initiation of androgen deprivation therapy.
引用
- O'Sullivan JM, Carles J, Cathomas R, et al. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. Eur Urol Oncol. 2019. PMID: 31411991. doi:10.1016/j.euo.2019.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。